UCB Award for Neuroscientific Research Presented to leading Belgian Neuroscience Group
Brussels (Belgium), 13 June 2006 - 5:00 pm CET. The UCB Award for Neuroscientific Research in Belgium is presented today to the research group of Dr. Pierre Vanderhaeghen, the Institut de Recherches Interdisciplinaires en Biologie Humaine et Moleculaire (IRIBHM), Université Libre de Bruxelles. This Award recognises the team's outstanding contribution to neuroscience and the understanding of the mechanisms that control the size and shape of the brain.
Her Royal Highness Princess Astrid, Honorary President of the Queen Elizabeth Medical Foundation, presented today the UCB Award for Neuroscientific Research at the Royal Palace in Brussels.
Dr. Pierre Vanderhaeghen is leading one of the seventeen university teams who received a substantial annual grant from the Queen Elisabeth Medical Foundation. This Foundation focuses on neuroscience and supports researchers using the latest techniques to study the functioning of the nervous system.
"As a global biopharmaceutical leader specialising in severe diseases including central nervous system disorders (CNS), UCB is pleased to support this award," said UCB's Chief Executive Officer, Roch Doliveux. "UCB is well aware of the essential role of academic research and has a history of strong partnerships with universities in Belgium, in addition to its own CNS Research Centre of Excellence in Braine l'Alleud."
In CNS research, UCB is focused on severe diseases that are physically and socially disabling and include epilepsy, narcolepsy, neuropathic pain and multiple sclerosis. The UCB Institute of Epilepsy in Belgium is pleased to offer a range of interactive services designed to help people living with epilepsy. UCB also proudly supports a range of other innovative educational, research and other epilepsy initiatives worldwide.
UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories. Employing 8 300 people in 40 countries, UCB achieved revenues of EUR 2.3 billion in 2005. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters are located in Brussels, Belgium.
Inquiries, please contact:
Corporate Communications and Investor Relations
Stay up-to-date on the latest news and information from UCB